RAPGEF1 and gastric cancer: Collectively, these multifaceted mechanisms highlight C3G’s potential as a therapeutic agent in gastric cancer treatment, particularly given the results of this study that C3G interacts with key molecular targets such as PTGS2 and HSP90AA1, which are crucial for cancer cell proliferation and survival [65,66].